You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 8,530,189

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,530,189

Title:	Sustained drug delivery system
Abstract:	A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.
Inventor(s):	Farinas; Kathleen Cogan (Los Altos, CA), Chamow; Steven (San Mateo, CA)
Assignee:
Application Number:	13/088,354
Patent Claims:	1. A method for manufacturing a drug composition comprising: coupling at least one positively charged moiety to a therapeutic compound, wherein the positively charged moiety is a peptide consisting of the amino acid sequence KGSKGSKGSKGSK (SEQ ID NO:1), KGKSKGKSK (SEQ ID NO:2), KGSKGSK (SEQ ID NO:3), or KGKSK (SEQ ID NO:4), and wherein the therapeutic compound is an anti-VEGF compound, wherein the spacing of positive charges on the peptide is configured to interact with a spatial arrangement of negative charges on an anionic component to create an in situ depot for prolonged delivery of the anti-VEGF compound. 2. The method of claim 1, wherein the coupling is achieved through a chemical process. 3. The method of claim 1, wherein the coupling is achieved through a recombinant DNA technique. 4. The method of claim 1, wherein the coupling is achieved using a stable covalent bond or a chemically labile covalent bond. 5. The method of claim 1, wherein the anionic component is present in tissue. 6. The method of claim 5, wherein the tissue is eye tissue. 7. The method of claim 6, wherein the eye tissue is vitreous. 8. The method of claim 1, wherein the anionic component is a glycosaminoglycan. 9. The method of claim 8, wherein the glycosaminoglycan is hyaluronic acid. 10. The method of claim 1, wherein the anti-VEGF compound is Bevacizumab. 11. The method of claim 1, wherein the anti-VEGF compound is Ranibizumab. 12. The method of claim 1, wherein the anti-VEGF compound is VEGF Trap.

Details for Patent 8,530,189

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2028-10-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2028-10-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.